Navigation Links
ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema

- Hereditary Angioedema (HAE) and the Dawn of New Therapeutics -

EXTON, Pa., March 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio webcast of its 'Teach-in' educational event for investors on Hereditary Angioedema (HAE), on Tuesday, March 10, 2009. Lectures will be provided by Anthony J. Castaldo and Janet Long, president and vice president, respectively, of the U.S. Hereditary Angioedema Association (HAEA), and Aleena Banerji, M.D., an HAE specialist at Massachusetts General Hospital.

The 'Teach-in', entitled 'Hereditary Angioedema (HAE) and The Dawn of New Therapeutics' will be held from 5:00 P.M. until 6:30 P.M. Eastern Time on Tuesday March 10, 2009.

"We are thrilled to enlist the participation of these key opinion leaders in the field of hereditary angioedema, who each day deal with the severe ramifications of HAE in their patients, families, and constituents," commented Will Roberts, ViroPharma's vice president of corporate communications. "As the proud stewards of the only approved C1 inhibitor therapy on the market, ViroPharma is committed to fostering our role as leaders in the space through the execution of essential disease awareness and investor programs."

A live audio webcast of the meeting may be accessed via the investor section of the ViroPharma corporate website, The archive of the meeting will be available through March 24, 2009.

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 30 years in Europe to treat patients with C1 inhibitor deficiency. Cinryze has not been approved for acute treatment in the United States or any other jurisdiction.

Cinryze has been well tolerated. The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.

Cinryze is for intravenous use only. A dose of 1000 Units Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
2. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
3. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. ViroPharma Provides Update on Vancocin(R)
5. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
6. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
7. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
8. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
9. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Association meeting in Washington D.C. revolved around the fact that proper dental care, both ... talk stressed the link between periodontal disease (more commonly referred to as gum disease) ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a ... X. With ProSidebar: Fasion, video editors can easily add an informative sidebar to ... title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the German ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology: